In Ontario, four research teams are turning an often-overlooked resource — the blood, tissue, and genetic data already donated by cancer patients — into a new frontier of discovery. Funded through the OICR's CATALYST program, these studies apply advanced genomic tools to existing samples, asking questions the original research was never designed to answer. It is a quiet but meaningful shift in scientific philosophy: honoring what patients have already given by extracting every possible insight from it, and shortening the long road between laboratory finding and clinical care.
Four OICR Studies Leverage Patient Data to Advance Cancer Detection and Treatment
Cancer patients generously donate samples and time; these studies aim to honor their contributions by advancing treatments that could improve survival outcomes.
Taking data already in hand and pushing it further with new methods
Mark
Why does it matter that these studies are reusing existing data instead of collecting new samples?
Mimi
Because every month a discovery sits in a lab notebook is a month a patient isn't benefiting from it. These researchers have thousands of samples already collected. Using new technology to ask new questions of that material means you can go from idea to clinical trial much faster.
Mark
But isn't there a risk that reanalyzing old data will just confirm what people already know?
Mimi
That's the tension, yes. But these aren't fishing expeditions. Each project has a specific hypothesis based on recent breakthroughs. The metformin study, for instance, builds on a very recent finding about how the drug affects a particular mutation. They're not just looking at old data—they're looking at it with new eyes.
Mark
What does it mean that patients are described as "partners" in this research?
Mimi
It means acknowledging that without their willingness to donate blood, tissue, and time, none of this happens. A lot of research talks about patients as subjects. This framing says they're collaborators with a stake in the outcome.
Mark
How long before any of these findings actually change how doctors treat patients?
Mimi
That depends on the results. If the blood tests work as hoped, you could see them in clinical use within a couple of years. The metformin study might take longer because it's about prevention, not treatment—you need to follow patients over time to know if it actually stops blood cancers from developing.
Mark
Is there a risk that focusing on blood biomarkers means some patients get left behind?
Mimi
That's always the question with precision medicine. These tests work best when you have clear genetic or molecular markers. Some cancers are messier than that. But the alternative is treating everyone the same way, which we know doesn't work either.
Le Pouls
- Thousands of patient samples sit in freezers holding answers to urgent cancer questions — CATALYST was created precisely to unlock them before more time is lost.
- Four distinct cancers are in the crosshairs: blood cancers that may be preventable with a diabetes drug, immunotherapy mismatches that waste precious treatment time, head and neck cancers that return without warning, and a rare blood cancer whose only cure carries devastating risks.
- Researchers are racing to validate blood-based tests that could tell doctors — before treatment fails — which patients will respond and which will relapse, replacing guesswork with genomic precision.
- A patient partner's voice anchors the entire effort: survivors who donated samples want proof their sacrifice moved medicine forward, and these studies are designed to deliver that proof within two to three years.
In Ontario, four research teams are turning an often-overlooked resource — the blood, tissue, and genetic data already donated by cancer patients — into a new frontier of discovery. Funded through the OICR's CATALYST program, these studies apply advanced genomic tools to existing samples, asking questions the original research was never designed to answer. It is a quiet but meaningful shift in scientific philosophy: honoring what patients have already given by extracting every possible insight from it, and shortening the long road between laboratory finding and clinical care.
The Ontario Institute for Cancer Research has taken an unconventional turn in cancer science: rather than launching entirely new experiments, its CATALYST program funds researchers to reanalyze data and samples already collected from patients — applying newer technologies to questions the original studies were never built to answer. The result is four simultaneous projects that could compress years of research into a much shorter path to the clinic.
One study examines whether metformin, a widely used diabetes medication, might prevent blood cancers in people who carry a genetic mutation linked to a condition called clonal hematopoiesis. Another investigates whether fragments of genetic material known as endogenous retrotransposable elements, detectable in a simple blood draw, could predict which patients will benefit from immunotherapy — potentially sparing others from treatments unlikely to help them.
A third project is developing a blood test for head and neck cancer patients, searching for circulating tumor DNA that might signal a coming relapse before it becomes visible through conventional means. The fourth tackles myelofibrosis, a rare blood cancer whose only cure — bone marrow transplant — carries serious risks. Researchers there are refining an existing risk-scoring tool to identify which patients are truly ready for transplant and when.
What unites all four efforts is a moral as much as a scientific logic. Cancer patients donate samples and time in the hope that their participation will matter. Vivian Simbul Sim, a survivor involved in reviewing the CATALYST projects, gave voice to that hope directly. By pushing existing data further with new methods, these studies aim to honor those contributions — and to deliver answers faster than traditional research timelines would ever allow.
The Ontario Institute for Cancer Research has launched four new studies that take an unusual approach to cancer science: instead of starting from scratch, they're mining existing patient data and tissue samples to answer urgent clinical questions. The work is funded through CATALYST, a new program designed to squeeze maximum value from the donations patients have already made to research—their blood, their tumors, their time.
Each of the four projects tackles a different cancer challenge, but they share a common logic. Researchers have already collected samples and genetic information from hundreds or thousands of patients. Rather than let that material sit in freezers, the CATALYST studies apply new technologies and analytical methods to ask questions the original research wasn't designed to answer. It's a form of scientific recycling, but one that could accelerate the path from lab discovery to hospital bedside.
The first study, led by Dr. Neil Fleshner at Princess Margaret Cancer Centre, builds on a surprising finding: a common diabetes drug called metformin appears to slow the growth of cells that carry a dangerous genetic mutation. That mutation causes a condition called clonal hematopoiesis, which dramatically raises the risk of blood cancers. Fleshner's team will use genetic testing on existing patient samples to explore whether metformin could actually prevent these cancers from developing in the first place.
A second team, including Dr. Hon Leong and Dr. Lillian Siu, is investigating whether a simple blood test could predict which cancer patients will respond to immunotherapy. Earlier work showed that patients whose tumors contained high levels of genetic material called endogenous retrotransposable elements—or EREs—responded better to immune checkpoint inhibitors. Now the researchers will test whether measuring those same elements in blood samples could serve as a predictor, potentially sparing patients from treatments unlikely to help them.
The third project focuses on head and neck cancer. Dr. Enrique Sanz Garcia and Dr. Scott Bratman are developing a blood test to identify patients at high risk of recurrence after treatment. The approach involves looking for tiny fragments of tumor DNA circulating in the bloodstream and determining whether their presence signals that cancer will return. If successful, such a test could guide decisions about follow-up care and intensity of surveillance.
The fourth study addresses a rare but serious condition: myelofibrosis, a blood cancer for which bone marrow transplant is the only cure—but one with severe side effects. Dr. Vikas Gupta and Dr. James Kennedy have already developed a risk-scoring tool for the disease. They will now reanalyze their data to determine whether the score can identify which patients are actually suitable for transplant and at what point in their treatment they would benefit most from it.
What ties these projects together is not just their focus on blood-based biomarkers or their use of existing data. It's a commitment to honoring patient contributions. Cancer patients who donate samples and participate in research do so with the hope that their participation will advance treatment for others. Vivian Simbul Sim, a cancer survivor and patient partner involved in reviewing the CATALYST projects, emphasized that patients want to know their involvement is making a tangible difference. These four studies, by taking data already in hand and pushing it further with new methods, aim to deliver on that promise more quickly than traditional research timelines would allow.
Citations marquantes
Patients who take part in research want to know that their participation is making a difference for the future of cancer care, and these studies are doing justice to their contributions.— Vivian Simbul Sim, cancer survivor and patient partner
By reanalyzing samples and data that have already been collected using new and innovative methods, these studies are maximizing research efficiency and narrowing the gap between science and clinical practice.— Dr. Lincoln Stein, OICR Acting Scientific Director
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine